# Sven H. Borho, CFA
Sven H. Borho, CFA, is a German-trained investment manager who co-founded OrbiMed, the healthcare investment firm, and served as its Managing Partner and head of public equity until his departure from the firm in 2026.[1](https://www.orbimed.com/leadership/sven-h-borho-cfa-2/) • [2](https://citywire.com/investment-trust-insider/news/orbimed-founder-sven-borho-steps-down-with-immediate-effect/a2495397) He joined OrbiMed's predecessor firm in 1991, became a portfolio manager in 1993, and for over three decades ran OrbiMed's public equity and hedge fund strategies, including the £1.3 billion Worldwide Healthcare Trust, which he managed from 2013.[1](https://www.orbimed.com/leadership/sven-h-borho-cfa-2/) • [2](https://citywire.com/investment-trust-insider/news/orbimed-founder-sven-borho-steps-down-with-immediate-effect/a2495397)
| Fact | Detail |
|---|---|
| Role | Co-founder and Managing Partner of OrbiMed; head of public equity; portfolio manager for OrbiMed's public equity and hedge funds[1](https://www.orbimed.com/leadership/sven-h-borho-cfa-2/) |
| Career start | Joined OrbiMed's predecessor firm in 1991 as a Senior Analyst covering European pharmaceuticals and worldwide biotechnology; portfolio manager since 1993[1](https://www.orbimed.com/leadership/sven-h-borho-cfa-2/) |
| Education | Business administration studies at Bayreuth University, Germany; M.Sc. (Econs.), Accounting and Finance, London School of Economics[1](https://www.orbimed.com/leadership/sven-h-borho-cfa-2/) |
| Trust management | Managed the £1.3bn Worldwide Healthcare Trust from 2013 until his 2026 departure[2](https://citywire.com/investment-trust-insider/news/orbimed-founder-sven-borho-steps-down-with-immediate-effect/a2495397) |
| Board seats | Sinovac Biotech (Independent Non-Executive Director, from 26 March 2025); Worldwide Healthcare Trust Plc (from 6 June 2018); The Biotech Growth Trust Plc (until 15 May 2018)[3](https://www.marketscreener.com/insider/SVEN-BORHO-A04ASI/) |
| Departure | Stepped down from OrbiMed with immediate effect in 2026 after 35 years[2](https://citywire.com/investment-trust-insider/news/orbimed-founder-sven-borho-steps-down-with-immediate-effect/a2495397) |
## Education and early career
Borho studied business administration at Bayreuth University in Germany and received an M.Sc. (Econs.) in [Accounting](https://www.edgepedia.org/accounting) and Finance from the [London School of Economics](https://www.edgepedia.org/london-school-of-economics).[1](https://www.orbimed.com/leadership/sven-h-borho-cfa-2/) He also holds the [Chartered Financial Analyst](https://www.edgepedia.org/chartered-financial-analyst) credential, reflected in the professional designation he uses.[1](https://www.orbimed.com/leadership/sven-h-borho-cfa-2/) • [3](https://www.marketscreener.com/insider/SVEN-BORHO-A04ASI/)
He started his career in 1991 at OrbiMed's predecessor firm as a Senior Analyst covering European pharmaceutical companies and biotechnology companies worldwide.[1](https://www.orbimed.com/leadership/sven-h-borho-cfa-2/) He has been a portfolio manager for the firm's funds since 1993, and the firm's leadership page credits him with playing an integral role in the growth of OrbiMed's asset management activities.[1](https://www.orbimed.com/leadership/sven-h-borho-cfa-2/)
## OrbiMed: role and structure
OrbiMed's profile describes Borho as a founder and Managing Partner who heads the public equity team and serves as portfolio manager for the firm's public equity and hedge funds.[1](https://www.orbimed.com/leadership/sven-h-borho-cfa-2/) MarketScreener's profile records Borho as a Managing Partner of OrbiMed Advisors LLC and of OrbiMed Advisors Private Equity and a portfolio manager at OrbiMed Capital LLC.[3](https://www.marketscreener.com/insider/SVEN-BORHO-A04ASI/)
The private equity operation Borho co-manages invests across North America, Asia, Europe, and Israel in biopharmaceuticals, medical technology, and healthcare services, participating in seed-stage, early-stage, and growth transactions, and also provides debt capital and monetizes royalty streams.[3](https://www.marketscreener.com/insider/SVEN-BORHO-A04ASI/) Borho's own mandate sat on the liquid side of that structure, running public equity and hedge fund vehicles rather than the venture funds.[1](https://www.orbimed.com/leadership/sven-h-borho-cfa-2/)
## Board seats and public positions
Borho's listed company roles have centered on healthcare investment trusts and a vaccine maker:
- **Sinovac Biotech Ltd.**: Independent Non-Executive Director since 26 March 2025.[3](https://www.marketscreener.com/insider/SVEN-BORHO-A04ASI/)
- **Worldwide Healthcare Trust Plc**: director from 6 June 2018; at his 2026 exit from management he intended to step down from the board in due course.[3](https://www.marketscreener.com/insider/SVEN-BORHO-A04ASI/) • [2](https://citywire.com/investment-trust-insider/news/orbimed-founder-sven-borho-steps-down-with-immediate-effect/a2495397)
- **The Biotech Growth Trust Plc**: board member until 15 May 2018.[3](https://www.marketscreener.com/insider/SVEN-BORHO-A04ASI/)
## The 2026 departure
In 2026, Borho stepped down from OrbiMed with immediate effect after 35 years, including from his role running the £1.3 billion Worldwide Healthcare Trust, which he had managed since 2013.[2](https://citywire.com/investment-trust-insider/news/orbimed-founder-sven-borho-steps-down-with-immediate-effect/a2495397) Trevor Polischuk, who had co-run the trust alongside Borho for over a decade, assumed the lead manager role. Geoff Hsu, a general partner at OrbiMed who joined the firm in 2002, joined as co-portfolio manager.[2](https://citywire.com/investment-trust-insider/news/orbimed-founder-sven-borho-steps-down-with-immediate-effect/a2495397)
The succession split along sector lines. Winterflood, the broker, expected Polischuk's focus on pharmaceuticals and broader healthcare themes to be complemented by Hsu's biotechnology specialism, which represented about a fifth (20%) of the trust's portfolio at the handover.[2](https://citywire.com/investment-trust-insider/news/orbimed-founder-sven-borho-steps-down-with-immediate-effect/a2495397) Winterflood also noted that the immediacy of the team changes, with no stated handover period, was "reasonably uncommon".[2](https://citywire.com/investment-trust-insider/news/orbimed-founder-sven-borho-steps-down-with-immediate-effect/a2495397)
## References
1. [Sven H. Borho, CFA - OrbiMed](https://www.orbimed.com/leadership/sven-h-borho-cfa-2/)
2. [OrbiMed founder Sven Borho steps down with immediate effect - Citywire Investment Trust Insider](https://citywire.com/investment-trust-insider/news/orbimed-founder-sven-borho-steps-down-with-immediate-effect/a2495397)
3. [Sven Borho: Positions, Relations and Network - MarketScreener](https://www.marketscreener.com/insider/SVEN-BORHO-A04ASI/)
---
*Topic: Encyclopedia › Society and history › Economics and business › Founders, operators, and investors › Venture and growth investors › Life-science venture and company creation › Biotech venture capital partners › Titles K to Z*
*Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026 · Edited: Sep 30, 2026; Oct 11, 2026; Oct 25, 2026 · Last review: Sep 30, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license